Umbilical cord mesenchymal stem cell therapy - Shanghai Life Science And Technology
Latest Information Update: 03 Nov 2022
At a glance
- Originator Shanghai Life Science and Technology
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Idiopathic pulmonary fibrosis
Most Recent Events
- 24 Oct 2022 Phase I/II trial in Idiopathic pulmonary fibrosis in China (Infusion) (NCT05468502)
- 27 Jul 2022 Preclinical trials in Idiopathic pulmonary fibrosis in China (Parenteral) (NCT05468502)
- 21 Jul 2022 Shanghai Life Science and Technology plans a phase I trial for Idiopathic pulmonary fibrosis in China (Parenteral) (NCT05468502)